NCT00080327已完成4 期
A Placebo-Controlled Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.1 个研究点 分布在 1 个国家目标入组 370 人开始时间: 2003年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 370
- 试验地点
- 1
- 主要终点
- Change at endpoint in schizophrenia rating scale
研究概览
简要总结
A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women, ages 18 and older, with a worsening of schizophrenia symptoms over the past three months
排除标准
- 未提供
研究组 & 干预措施
1
Active Comparator
干预措施: Aripiprazole (Drug)
2
Active Comparator
干预措施: Aripiprazole (Drug)
3
Active Comparator
干预措施: Aripiprazole (Drug)
4
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change at endpoint in schizophrenia rating scale
次要结局
- Clinical Global Improvement scale at endpoint and time to response
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant TherapyMajor Depressive DisorderNCT00683852Massachusetts General Hospital225
已完成
3 期
Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's TypeDementia, Alzheimer TypeNCT01438060Otsuka Pharmaceutical Development & Commercialization, Inc.232
已完成
3 期
Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression EpisodeBipolar DisorderNCT00080314Otsuka Pharmaceutical Development & Commercialization, Inc.400
已完成
3 期
Study of Aripiprazole in Patients With Acute Bipolar ManiaBipolar DisorderNCT00097266Otsuka Pharmaceutical Development & Commercialization, Inc.615
已完成
3 期
A Study of Adjunctive Aripiprazole in Participants With Major Depressive DisorderMajor Depressive DisorderNCT00095758Otsuka Pharmaceutical Development & Commercialization, Inc.1,151